Shanchun Guo

Back to Journals » Biologics: Targets and Therapy » Volume 19 Authors Guo S , Sidhu R, Ramar V, Guo AA, Wang G, Liu M Received 21 December 2024 Accepted for publication 1 March 2025 Published 5 April 2025 Volume 2025:19 Pages 157—176 DOI https://doi.org/10.2147/BTT.S509774 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Shein-Chung Chow Shanchun Guo,1 Rajveer Sidhu,2 Vanajothi Ramar,2 Alyssa A Guo,3 Guangdi Wang,1...

Introduction Click to copy section linkSection link copied! ROS1 is a receptor tyrosine kinase encoded by the ROS1 proto-oncogene. (1) Chromosomal rearrangements involving ROS1 and a fusion partner generate constitutively active ROS1 fusion kinases that are oncogenic drivers in human cancers. (2) ROS1 fusions are found in approximately 2% of late-stage nonsmall cell lung cancer (NSCLC) with CD74-ROS1 and SLC34A2-ROS1 as the most common rearrangements.

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.